drugset / Trial / NCT06049017

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06049017

Phase 2 Completed 252 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.

Timeline

Start
2023-10-09
Primary completion
2024-09-26
Completion
2026-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotrokinra Peptide Oral

Indications